Moses Judah Folkman 1933–2008

نویسنده

  • P. Gold
چکیده

CURRENT ONCOLOGY—VOLUME 15, NUMBER 1 4 Copyright © 2008 Multimed Inc. On January 14, a bright light in the field of cancer research was extinguished with the sudden death of Dr. Judah Folkman. Folkman first introduced the concept of tumour angiogenesis as a key factor in tumour growth and a target for tumour therapy in 1970. Despite the great skepticism accorded his work, he persisted in his studies. His efforts were eventually vindicated and reproduced in numerous laboratories. Indeed, an enormous number of labs continue to work in the field that Judah Folkman initiated, and about a dozen anti-angiogenic drugs are already on the market. A native of Cleveland, Ohio, Judah Folkman earned his Bachelor of Arts cum laude from Ohio State University in 1953, and his MD magna cum laude from Harvard Medical School in 1957. While an undergraduate, he worked in Dr. Robert Zollinger’s surgical laboratory and co-authored papers describing a new method of hepatectomy for liver cancer. As a student at Harvard Medical School, he worked in Dr. Robert Gross’s laboratory, where he developed the first atrioventricular implantable pacemaker, for which he received the Boylston Medical Prize, the Soma Weiss Award, and the Borden Undergraduate Award in Medicine. In 1957, Folkman began his surgical training at the Massachusetts General Hospital, serving as its chief resident in surgery in 1964–1965. That residency was interrupted between 1960 and 1962, when he served as a lieutenant in the U.S. Navy at the National Naval Medical Center in Bethesda. It was there that he, along with colleague Dr. David Long, first demonstrated the sustained release of drugs from implantable silicone rubber polymers that led to the development of the Norplant 5-year contraception system and initiated the field of controlled-release technology. It was also in Bethesda that Folkman carried out experiments growing tumours in isolated perfused organs, which led to the idea that tumours are angiogenesis-dependent, requiring new blood vessels to survive. In 1965, Folkman joined Harvard’s surgical service, and in 1967, he was promoted to Professor of Surgery at Harvard Medical School and to surgeonin-chief at the Children’s Hospital Medical Center, becoming the Julia Dyckman Andrus Professor of Pediatric Surgery in 1968. Folkman’s discoveries related to the mechanism of angiogenesis opened a field of investigation now pursued worldwide. This work elaborated the hypothesis that tumours can grow only if accompanied by the development of feeder blood vessels—that is, angiogenesis—and that malignancy may depend in part on proteins that stimulate vascular growth. His laboratory reported the first purified angiogenesis molecule and the first angiogenesis inhibitor, proposed the concept of angiogenic disease, and initiated clinical trials based on that research. He developed almost all of the methodology for the field, including the first cloning and culture of capillary endothelial cells, and sustained-release polymer technology, together with the in vivo bioassays for the various phenomena involved. He elucidated the sequential steps of capillary networks, and he proposed a linkage between cell shape and growth, currently understood in terms of mechanochemical mediation of gene expression by cytoskeletal elements. Folkman’s exceptional achievements have been recognized with numerous national and international awards. On three separate occasions, he delivered the commencement address at Harvard Medical School. He was elected to the National Academy of Sciences and was a member of the American Academy of Arts and Sciences, the American Philosophical Society, and the Institute of Medicine. Folkman also received a Gairdner Foundation International Award and a Christopher Columbus Discovery Award in Biomedical Research from the National Institutes of Health. He was a recipient of the Wolf Prize in Medicine from Israel. In 1993, he received the Lucian Award and a DSc (Honoris Causa) from McGill University (among his dozen or more honorary degrees). Judah Folkman was a superb doctor, a brilliant investigator, and a good friend. He will be much missed. Moses Judah Folkman 1933–2008

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Angiogenesis and the progress of vascular and tumor biology: a tribute to Judah Folkman.

On February 24, 2008, Judah Folkman would have celebrated his 75th birthday. However, as announced in the February issue ofThrombosis and Haemostasis, he suddenly passed away on January 14, 2008, while crossing the US continent pursuing his mission: to communicate the results and the clinical benefits gained from 40 years of endless, dedicated research. Among the over hundred awards and prices ...

متن کامل

Judah Folkman 1933–2008

When Bruce Zetter called me late at night on January 14 with news of Judah Folkman’s passing, my shock and grief were almost as great as when I learned, 8 years earlier, of my own father’s sudden death. I suspect many people shared my reaction, especially fellow researchers in the field of tumor angiogenesis. After all, he was widely acknowledged to be the father of the field, and a doting one ...

متن کامل

By RICHARD G . AZIZKHAN , JANE CLIFFORD AZIZKHAN , BRUCE R . ZETTER , : I : AND JUDAH FOLKMAN

It is now recognized that angiogenesis, the induction of capillary proliferation, is important for the continued growth of solid tumors (1-3). Kessler et al. (4) reported that mast cells assemble at a tumor site before the ingrowth of new capillaries; it was proposed that mast cells may play a role in tumor angiogenesis. Mast cells are also found in increased numbers in other pathologic states ...

متن کامل

The antitumorigenic trifecta.

The laboratory of Judah Folkman identified the potent endogenous antiangiogenic protein angiostatin in 1994.(1) In this issue of Blood, Lee and colleagues propose 2 new mechanisms of action for angiostatin that may represent promising targets for new cancer therapeutics.(2).

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Current Oncology

دوره 15  شماره 

صفحات  -

تاریخ انتشار 2008